Piscataway, NJ, November 27, 2023–Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspension, USP to its current portfolio.
Famotidine Powder for Oral Suspension, USP is indicated:
In adults for the treatment of:
- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy.
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.
In pediatric patients 1 year of age and older for the treatment of:
- peptic ulcer disease.
- GERD with or without esophagitis and ulcerations.
In pediatric patients from birth to less than 1 year of age for the treatment of:
- GERD.
Famotidine 40 mg/5 mL Powder for Oral Suspension, USP is available in a bottle to make 50 mL when reconstituted as directed.
To find out more about Famotidine Powder for Oral Suspension, USP please visit www.camberpharma.com/famotidine-pfos
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
